Tectonic Therapeutic (TECX) Competitors $20.73 -1.46 (-6.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.89 +0.16 (+0.77%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TECX vs. SRPT, ADPT, SDGR, EVO, EWTX, JANX, ABCL, ANIP, TVTX, and ETNBShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Sarepta Therapeutics (SRPT), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), Evotec (EVO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), AbCellera Biologics (ABCL), ANI Pharmaceuticals (ANIP), Travere Therapeutics (TVTX), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. Its Competitors Sarepta Therapeutics Adaptive Biotechnologies Schrodinger Evotec Edgewise Therapeutics Janux Therapeutics AbCellera Biologics ANI Pharmaceuticals Travere Therapeutics 89BIO Sarepta Therapeutics (NASDAQ:SRPT) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Which has stronger earnings and valuation, SRPT or TECX? Sarepta Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$2.23B0.70$235.24M-$2.69-5.91Tectonic TherapeuticN/AN/A-$57.98M-$7.31-2.84 Does the media favor SRPT or TECX? In the previous week, Sarepta Therapeutics had 118 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 122 mentions for Sarepta Therapeutics and 4 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.89 beat Sarepta Therapeutics' score of 0.28 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 19 Very Positive mention(s) 17 Positive mention(s) 65 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral Tectonic Therapeutic 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SRPT or TECX more profitable? Tectonic Therapeutic has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -11.12%. Sarepta Therapeutics' return on equity of -14.88% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics-11.12% -14.88% -5.12% Tectonic Therapeutic N/A -30.13%-27.52% Do analysts rate SRPT or TECX? Sarepta Therapeutics presently has a consensus target price of $49.12, indicating a potential upside of 208.74%. Tectonic Therapeutic has a consensus target price of $80.33, indicating a potential upside of 287.52%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 5 Sell rating(s) 16 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.10Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders have more ownership in SRPT or TECX? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, SRPT or TECX? Sarepta Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, suggesting that its share price is 227% more volatile than the S&P 500. SummarySarepta Therapeutics and Tectonic Therapeutic tied by winning 8 of the 16 factors compared between the two stocks. Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$414.34M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-2.8417.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book2.178.508.275.55Net Income-$57.98M-$55.06M$3.24B$259.03M7 Day Performance-7.12%-3.98%-3.69%-4.59%1 Month Performance-1.71%9.59%4.33%4.46%1 Year Performance20.87%6.72%25.95%18.03% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic2.8726 of 5 stars$20.73-6.6%$80.33+287.5%+16.7%$414.34MN/A-2.84120News CoverageGap UpSRPTSarepta Therapeutics4.71 of 5 stars$16.14+16.4%$49.12+204.4%-89.0%$1.59B$1.90B-6.031,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeHigh Trading VolumeADPTAdaptive Biotechnologies3.0058 of 5 stars$10.35-2.5%$10.57+2.2%+132.1%$1.57B$178.96M-10.77790Positive NewsUpcoming EarningsGap DownSDGRSchrodinger2.5882 of 5 stars$21.30-4.9%$32.75+53.8%-13.6%$1.56B$207.54M-8.10790Positive NewsUpcoming EarningsGap DownEVOEvotec2.0865 of 5 stars$4.24-0.6%$5.90+39.3%-13.2%$1.51B$788.22M0.004,827News CoverageEWTXEdgewise Therapeutics2.2917 of 5 stars$14.03-1.6%$40.00+185.1%-14.6%$1.48BN/A-9.0560News CoverageUpcoming EarningsAnalyst ForecastJANXJanux Therapeutics2.4087 of 5 stars$24.69-3.4%$91.89+272.2%-43.2%$1.46B$10.59M-18.1130Positive NewsUpcoming EarningsGap UpABCLAbCellera Biologics2.4221 of 5 stars$4.76-3.3%$8.75+83.9%+39.0%$1.42B$23.11M-8.47500News CoverageUpcoming EarningsANIPANI Pharmaceuticals3.6554 of 5 stars$65.28-1.8%$78.88+20.8%+0.1%$1.41B$614.38M-51.40600Upcoming EarningsTVTXTravere Therapeutics1.9421 of 5 stars$15.68+1.8%$32.14+105.0%+69.2%$1.39B$273.53M-5.58460Positive NewsShort Interest ↑ETNB89BIO2.0459 of 5 stars$9.26-2.9%$26.43+185.3%-3.1%$1.35BN/A-2.7440Positive NewsUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Sarepta Therapeutics Competitors Adaptive Biotechnologies Competitors Schrodinger Competitors Evotec Competitors Edgewise Therapeutics Competitors Janux Therapeutics Competitors AbCellera Biologics Competitors ANI Pharmaceuticals Competitors Travere Therapeutics Competitors 89BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
